ReviewFrontiers in medical technology2026
Nanosystems for delivery of indolicidin peptide.
Review in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of multidrug-resistant pathogens has necessitated the search for novel therapeutic alternatives such as antimicrobial peptides (AMPs). Indolicidin (Ind) represents a highly promising candidate owing to its broad-spectrum activity and multimodal mechanisms; however, its clinical translation is limited by rapid proteolytic degradation and intrinsic host cytotoxicity. To overcome these pharmacological bottlenecks, this review places nanocarrier based delivery of Ind at its analytical center, rigorously evaluating the integration of Ind into nanoscale delivery systems as a transformative therapeutic strategy. We critically analyze how diverse organic and inorganic platforms fundamentally reconfigure Ind's mechanism of action, including the bidirectional relationship between nanoparticle-generated ROS and peptide-mediated membrane disruption. Furthermore, we discuss emerging bio-inspired approaches utilizing stimuli-responsive hydrogels, lipid cubic phases, and liposomes for programmed intracellular release. A critical assessment of long-term genotoxicological and ecotoxicological safety profiles is subsequently provided to address mandatory regulatory prerequisites. This integrated analysis establishes a comprehensive mechanistic and translational framework for the rational development of next-generation Ind-based antimicrobial nanomedicines, balancing structural tethering with supramolecular assembly to effectively combat antibiotic-resistant infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.